PT  - JOURNAL ARTICLE
AU  - Oday Elmanaseer
AU  - Alzira R M Avelino
AU  - Amin Azem
AU  - Mihir Raval
TI  - Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia
AID  - 10.1136/bcr-2021-245557
DP  - 2021 Dec 01
TA  - BMJ Case Reports
PG  - e245557
VI  - 14
IP  - 12
4099  - http://casereports.bmj.com/content/14/12/e245557.short
4100  - http://casereports.bmj.com/content/14/12/e245557.full
SO  - BMJ Case Reports2021 Dec 01; 14
AB  - Serum sickness (SS) is a known phenomenon; however, it is commonly missed due to vague symptoms, and is usually confounded by other aetiologies that present similarly. Obinutuzumab is a novel anti-CD20 antibody agent that has been approved for chronic lymphocytic leukaemia (CLL) treatment. At the time of approval, it was not linked to SS; however, this phenomenon has been recognised with other anti-CD20 agents like rituximab. SS remains a rare entity, but it is important to be recognised accurately and quickly in the appropriate circumstances, so that effective treatment with corticosteroids can be initiated to alleviate inflammatory symptoms. Here we present a patient with CLL who developed maculopapular rash, fever and polyarthritis and elevated inflammatory markers consistent with serum sickness triggered by obinutuzumab and was effectively treated with corticosteroids.